KLOW ships as an 80 mg lyophilized powder. Before it can be used in any laboratory procedure it has to be reconstituted — dissolved in a measured volume of diluent — and the volume chosen determines the concentration of every component in the vial. This page sets out the arithmetic and provides the resulting concentration tables.
What this page is not: it contains no dosing guidance, no administration schedule and no frequency recommendation, because KLOW is a research material with no established human or veterinary dosing. See why there is no dosing chart here.
What is in an 80 mg KLOW vial
KLOW is a four-component blend. The total mass matters for concentration, but so does the split, because the components are not present in equal amounts:
- GHK-Cu — 50 mg (62.5% of the vial)
- BPC-157 — 10 mg (12.5%)
- TB-500 — 10 mg (12.5%)
- KPV — 10 mg (12.5%)
Composition and ratios may vary by formulation; the figures above describe the KLOW 80 mg research listing. Always confirm against the lot-specific certificate of analysis.
The arithmetic
Reconstitution concentration is a single division:
concentration (mg/mL) = total mass (mg) ÷ diluent volume (mL)
For an 80 mg vial reconstituted with 2 mL, that is 80 ÷ 2 = 40 mg/mL of total peptide. Each individual component is then its own mass divided by the same volume — GHK-Cu at 50 ÷ 2 = 25 mg/mL, and each of the other three at 10 ÷ 2 = 5 mg/mL.
Adding diluent does not change how much peptide is in the vial. It only changes how concentrated the solution is, and therefore what volume corresponds to a given mass.
Concentration chart: total blend
| Diluent added | Total concentration | Peptide per 0.1 mL | 0.1 mL aliquots per vial |
|---|---|---|---|
| 1.0 mL | 80.0 mg/mL | 8.00 mg | 10 |
| 2.0 mL | 40.0 mg/mL | 4.00 mg | 20 |
| 3.0 mL | 26.67 mg/mL | 2.67 mg | 30 |
| 4.0 mL | 20.0 mg/mL | 2.00 mg | 40 |
| 5.0 mL | 16.0 mg/mL | 1.60 mg | 50 |
Concentration chart: per component
Because GHK-Cu makes up five-eighths of the vial, its concentration is always five times that of each other component. This is the table that matters if an experiment is designed around one constituent rather than the blend as a whole.
| Diluent | GHK-Cu 50 mg |
BPC-157 10 mg |
TB-500 10 mg |
KPV 10 mg |
|---|---|---|---|---|
| 1.0 mL | 50.0 mg/mL | 10.0 mg/mL | 10.0 mg/mL | 10.0 mg/mL |
| 2.0 mL | 25.0 mg/mL | 5.0 mg/mL | 5.0 mg/mL | 5.0 mg/mL |
| 3.0 mL | 16.67 mg/mL | 3.33 mg/mL | 3.33 mg/mL | 3.33 mg/mL |
| 4.0 mL | 12.5 mg/mL | 2.5 mg/mL | 2.5 mg/mL | 2.5 mg/mL |
| 5.0 mL | 10.0 mg/mL | 2.0 mg/mL | 2.0 mg/mL | 2.0 mg/mL |
Storage after reconstitution
- Lyophilized, unopened: −20 °C to −80 °C, sealed, protected from light and moisture, desiccated.
- Reconstituted, short term: up to 7 days at 4 °C.
- Reconstituted, longer term: −20 °C in single-use aliquots.
- Freeze–thaw: minimise cycles. Each one degrades peptide integrity, which is the argument for aliquoting at the point of reconstitution rather than repeatedly freezing one vial.
Why there is no dosing or frequency chart on this page
Searches for KLOW frequently ask for a dose per day or a dosing frequency chart, so it is worth being explicit rather than silently omitting it.
KLOW is not an approved product for human or veterinary use. No dosing has been established for it, because the blend has never been studied as a blend — the published literature examines its four constituents individually, overwhelmingly in cell culture and rodent models. There is no clinical evidence base from which a dose, a route, a schedule or a duration could be derived, and constructing one by combining preclinical figures would be inventing a number, not reporting one.
What can be stated factually is the concentration arithmetic above: how much peptide is present in a given volume once the vial is reconstituted. That is a property of the material. How it is used in a laboratory protocol is determined by the research design and the applicable institutional and regulatory requirements, not by a supplier page.
Frequently asked questions
How much diluent should be added to a KLOW 80 mg vial?
There is no single correct volume. Any volume between roughly 1 mL and 5 mL fully dissolves the powder; the choice determines the resulting concentration, shown in the tables above. 2 mL is a common working choice because it gives round numbers — 40 mg/mL total, 25 mg/mL GHK-Cu, 5 mg/mL for each of the other three.
Does adding more water make the vial weaker?
It makes the solution less concentrated, but the vial still contains 80 mg of peptide either way. More diluent means a larger volume corresponds to the same mass.
Why is the solution blue?
GHK-Cu is a copper (II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Copper coordination complexes are strongly coloured, so both the lyophilized powder and the reconstituted solution carry a blue tint. This is expected for any GHK-Cu-containing blend, including GLOW.
Can a reconstituted vial be refrozen?
It can, but each freeze–thaw cycle degrades peptide integrity. Aliquoting into single-use portions at the time of reconstitution avoids repeated cycling of the whole volume.
How long does reconstituted KLOW last?
Up to 7 days at 4 °C for short-term storage, or at −20 °C in aliquots for longer.
Is the reconstitution different for GLOW?
The procedure is identical. Only the arithmetic differs, because a GLOW vial contains 70 mg rather than 80 mg. See KLOW vs GLOW for the composition comparison.
Research use only
This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease. The information on this page describes the physical and chemical properties of a laboratory material. It is not medical advice, not a product claim, and not a use recommendation.